Imunon Inc
IMNN1.140USD
+0.724+174.37%
Fechamento 05/23, 16:00（ET）Cotações atrasadas em 15 min
16.67MValor de mercado
PerdaP/L TTM
Mais detalhes de Imunon Inc Empresa
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Informações da empresa
Código da empresaIMNN
Nome da EmpresaImunon Inc
Data de listagemOct 27, 1993
Fundado em2000
CEODr. Stacy R. Lindborg, Ph.D.
Número de funcionários25
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 27
Endereço997 Lenox Dr Ste 100
CidadeLAWRENCEVILLE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal08648
Telefone16098969100
Sitehttps://imunon.com/
Código da empresaIMNN
Data de listagemOct 27, 1993
Fundado em2000
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
69.14K
+66.55%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
25.60K
--
Dr. Sebastien Hazard
Dr. Sebastien Hazard
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
20.00K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
12.86K
+350.26%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
11.77K
--
Ms. Susan Eylward
Ms. Susan Eylward
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David (Dave) Gaiero, CPA
Mr. David (Dave) Gaiero, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Douglas Vincent Faller, M.D., Ph.D.
Dr. Douglas Vincent Faller, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
69.14K
+66.55%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
25.60K
--
Dr. Sebastien Hazard
Dr. Sebastien Hazard
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
20.00K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
12.86K
+350.26%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
11.77K
--
Ms. Susan Eylward
Ms. Susan Eylward
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: sex, 16 de mai
Tempo de atualização: sex, 16 de mai
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
Geode Capital Management, L.L.C.
0.98%
Tardugno (Michael H)
0.47%
BlackRock Institutional Trust Company, N.A.
0.40%
Le (Goff Corinne)
0.36%
The Vanguard Group, Inc.
0.33%
Other
97.45%
Estatísticas dos acionistas
Acionista
Proporção
Geode Capital Management, L.L.C.
0.98%
Tardugno (Michael H)
0.47%
BlackRock Institutional Trust Company, N.A.
0.40%
Le (Goff Corinne)
0.36%
The Vanguard Group, Inc.
0.33%
Other
97.45%
Tipo
Acionista
Proporção
Investment Advisor/Hedge Fund
1.68%
Individual Investor
1.52%
Investment Advisor
0.41%
Venture Capital
0.15%
Hedge Fund
0.10%
Other
96.14%
Participação acionária institucional
Tempo de atualização: seg, 3 de mar
Tempo de atualização: seg, 3 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
49
648.18K
4.43%
-1.83M
2024Q4
52
608.75K
4.16%
-1.78M
2024Q3
50
1.20M
8.34%
-536.74K
2024Q2
48
484.50K
4.81%
-359.07K
2024Q1
49
447.12K
4.68%
-585.60K
2023Q4
59
755.78K
7.96%
-79.04K
2023Q3
65
452.55K
4.85%
-471.22K
2023Q2
68
440.18K
4.85%
-489.81K
2023Q1
80
515.97K
6.03%
-572.90K
2022Q4
81
529.26K
7.22%
-671.21K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Geode Capital Management, L.L.C.
139.50K
0.95%
+13.57K
+10.78%
Dec 31, 2024
Tardugno (Michael H)
69.14K
0.47%
+27.63K
+66.55%
Feb 21, 2025
BlackRock Institutional Trust Company, N.A.
58.22K
0.4%
--
--
Dec 31, 2024
Le (Goff Corinne)
53.00K
0.36%
--
--
Feb 21, 2025
The Vanguard Group, Inc.
48.81K
0.33%
--
--
Dec 31, 2024
Lindborg (Stacy R. Ph.D.)
28.06K
0.19%
+3.06K
+12.22%
Feb 21, 2025
Braun (Donald P)
25.60K
0.18%
--
--
Feb 21, 2025
XTX Markets LLC
21.41K
0.15%
+21.41K
--
Dec 31, 2024
Northern Trust Investments, Inc.
21.64K
0.15%
+18.40K
+567.70%
Dec 31, 2024
State Street Global Advisors (US)
21.30K
0.15%
--
--
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: ter, 6 de mai
Tempo de atualização: ter, 6 de mai
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Data
Tipo
Proporção
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
